Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $220.75.
A number of equities analysts have recently issued reports on CRL shares. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Finally, Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st.
Check Out Our Latest Stock Analysis on Charles River Laboratories International
Charles River Laboratories International Price Performance
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same period in the prior year, the business posted $2.34 earnings per share. Charles River Laboratories International’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts predict that Charles River Laboratories International will post 11.05 earnings per share for the current year.
Insider Transactions at Charles River Laboratories International
In related news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in CRL. Invesco Ltd. boosted its position in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Charles River Laboratories International in the fourth quarter valued at approximately $176,478,000. Victory Capital Management Inc. lifted its stake in Charles River Laboratories International by 9,938.8% in the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after buying an additional 684,586 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after buying an additional 575,039 shares in the last quarter. Finally, Amundi grew its position in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after buying an additional 492,301 shares during the period. 98.91% of the stock is owned by institutional investors.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
